Technical Scrutiny: Novavax Inc., MannKind Corp., Galena Biopharma Inc., and
Ariad Pharma Inc.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, September 10, 2013
LONDON, September 10, 2013 /PRNewswire/ --
On Monday, September 9, 2013, the Dow Jones Industrial Average gained 0.94%,
while the S&P 500 and the NASDAQ Composite finished the day 1.00% and 1.26%
higher. Shares in the healthcare sector ended mostly on a higher note as the
broader market posted sharp gains. The major movers in the sector included
Novavax Inc. (NASDAQ: NVAX), MannKind Corporation (NASDAQ: MNKD), Galena
Biopharma Inc. (NASDAQ: GALE), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA).
AAAResearchReports.com has tracked NVAX, MNKD, GALE, and ARIA. These reports
can be seen for free at:
On Monday, Novavax Inc.'s stock surged by 3.70% after hitting a new 52-week
high of $3.47 as the US equity market rose sharply. The company's shares
fluctuated between $3.25 and $3.47 before ending the day at $3.36. A total of
3.05 million shares were traded, which is above the daily average volume of
2.37 million. The company's shares have rallied by 78.72% in the last three
months and 44.83% in the last one month, compared to a gain of 1.72% and a
loss of 1.17% in the S&P 500 during the respective periods. Moreover, the
stock is currently trading above its 50-day and 200-day moving averages.
Download free research on NVAX by signing up now at:
Shares in MannKind Corp. rose sharply on Monday, tracking gains in the broader
market. The company's shares oscillated between $5.80 and $6.00 before ending
the day at $5.98, which is 2.05% higher than the previous day's price of
$5.86. A total of 4.33 million shares were traded, which is below the daily
average volume of 8.89 million. Despite the gains on Monday, the company's
stock has lost 1.16% in the last three trading sessions, underperforming the
S&P 500 which has gained 1.13% during the same period. Further, MannKind
Corp.'s stock is trading above its 200-day moving averages of $4.48. Register
for today's free analysis on MNKD at:
Galena Biopharma Inc.'s stock moved higher on Monday, before closing the day
at $2.41, up 1.26% from the previous day's closing price of $2.38. The
company's shares oscillated between $2.38 and $2.47 during the trading
session. A total of 1.19 million shares were traded, which is below the daily
average volume of 1.67 million. The company's shares have surged by 9.05% in
the last three months and 23.59% in the last one month, outperforming the S&P
500 which gained 1.72% and lost 1.17% during the respective periods. Moreover,
the company's shares are trading above its 50-day and 200-day moving averages
of $2.03 and $2.05, respectively. A free report on GALE can be accessed by
Shares in Ariad Pharmaceuticals Inc. slipped on Monday, even as the broader
market rose sharply. The company's shares fluctuated between $21.65 and $22.90
before closing the day 2.06% lower at $21.85. A total of 5.91 million shares
were traded, which is more than the daily average volume of 2.38 million. The
company's shares have surged by 15.67% in the last three months and 18.56% in
the last one month, outperforming the S&P 500 which has gained 1.72% and lost
1.17% during the respective periods. Furthermore, the company's shares are
trading above its 50-day and 200-day moving averages of $19.02 and $19.33,
respectively. Register with AAA Research Reports and download research on ARIA
for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by an analyst. However, we are only human and are prone
to make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
SOURCE AAA Research Reports
Contact: Phone #: +1(646)396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.